—Researchers provide the most comprehensive genetic synopsis of primary biliary cholangitis to date, identifying 44 risk-associated variants with strong evidence for novel genome-wide significant loci ...

DelveInsight's,“ Primary Biliary Cholangitis Pipeline Insight 2025 ” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Primary Biliary Cholangitis pipeline landscape ...

Ahead of New York Fashion Week, Gilead Sciences is strutting its marketing stuff to raise awareness of primary biliary cholangitis (PBC). The pharma—which earned the FDA’s accelerated approval for PBC ...

Although PSC has no cure, you can manage liver damage with early diagnosis and treatment. Here’s how PSC and UC are connected, and what you can do if you have both. Like UC, PSC is a chronic ...

Findings showed a statistically significantly greater proportion of saroglitazar-treated patients achieved a biochemical response vs placebo (treatment difference, 48.5%; P .001). Topline data were ...

Cholangitis and cholecystitis are two conditions that share some similarities but have different causes and symptoms. Cholangitis affects the bile ducts, while cholecystitis affects the gallbladder.

AMSTERDAM — Norucholic acid (NCA), an investigational therapy, demonstrated significant superiority over placebo in halting disease progression in patients with primary sclerosing cholangitis (PSC), ...

Biopsies guided by high resolution ultrasound are as effective as those using MRI in diagnosing prostate cancer, an international clinical trial has shown. The technology, called micro-ultrasound, is ...

Jay N. Yepuri, MD, MS, FACG, is a board-certified gastroenterologist and member of the Digestive Health Associates of Texas Board of Directors and Executive Committee. Primary sclerosing cholangitis ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for Seladelpar Gilead (seladelpar lysine dihydrate) to treat primary biliary cholangitis (PBC). PBC is a chronic ...

Please provide your email address to receive an email when new articles are posted on . In line with an earlier panel decision, FDA denied full approval to Ocaliva for primary biliary cholangitis. FDA ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ...